Real-world comparison of BTKi monotherapy and fixed-duration BTKi–Venetoclax for first line treatment of chronic lymphocytic leukemia patients without TP53 mutations or IGHV rearrangement
Year: 2025
Type: conference-abstract
Source: Blood
Institutions: SUNY Upstate Medical University, St. Mary's Hospital
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417006581
Cites:
Cited by:
Related to: